A Phase 2 interventional study of rLP2086 and Repevax in Meningococcal Vaccine, rLP2086 and Repevax, sponsored by Pfizer. Completed at 36 sites in 3 countries. Open to participants aged 11 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-27.
Sponsored by Pfizer · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Meningitis by Pfizer — none open to participants now, none under way, none of them phase 3. Meningitis · Pfizer.
Among the 16 studies in Meningitis by Pfizer, this one is the only one that started in 2011, is the only one in phase 2, and was the 16th registered.
268 studies on the registry are indexed under Meningitis; 28 are open to participants now.
Browse Meningitis studies →None of the 16 studies in Meningitis by Pfizer is open now. The open studies under Meningitis, anywhere →
Of the 17 Meningitis studies recruiting now, 11 (65%) set no upper age limit and 6 (35%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.
This study: 11 Years to 18 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 753 is above the median of 260 across 185 interventional studies indexed under Meningitis.
Median enrollment 521 across the 4 interventional studies, 16,684 across the 2 observational. Of the 16 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Meningitis by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is to look at a new vaccine that might prevent meningococcal disease, and to look at the safety of the new vaccine as well as how it is tolerated when given together with Repevax. The study will be done in healthy adolescents.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
rLP2086 and Repevax
Biological: rLP2086 · Biological: Repevax
Saline and Repevax
Biological: Saline · Biological: Repevax
Drug pages: MenB-FHbp vaccine · 4CMenB vaccine
0.5 mL dose, given at 0, 2 and 6 months.
0.5 mL dose, given at 0 months.
0.5 mL dose, given at 0, 2 and 6 months.
0.5 mL dose, given at 0 months.
Percentage of Participants Achieving Prespecified Criteria for the Concomitant Antigen
Time frame: 1 month after Vaccination 1
Percentage of Participants With at Least One Adverse Event (AE)
Time frame: Vaccination 1 up to 1 month after Vaccination 3
Geometric Mean Concentration (GMC) for Diphtheria and Tetanus Antigens
Time frame: 1 month after Vaccination 1
GMC for Acellular Pertussis Antigens
Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EU/mL)
Time frame: 1 month after Vaccination 1
Geometric Mean Titer (GMT) for Poliomyelitis Antigens
Time frame: 1 month after Vaccination 1
Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal to (>=) Prespecified Titer Level
Time frame: 1 month after Vaccination 3
Immunoglobulin G (IgG) Measured by Geometric Mean Titer (GMT)
Time frame: Before vaccination 1, 1 month after Vaccination 2, 3
Geometric Mean Fold-Rise (GMFR) for IgG
Time frame: Before Vaccination 1, 1 month after Vaccination 2, 3
| Milestone | Group 1: rLP2086 + Repevax | Group 2: Saline+Repevax |
|---|---|---|
| Started | 373 | 376 |
| Completed | 330 | 347 |
| Not completed | 43 | 29 |
| Withdrew: Withdrawal by subject | 19 | 10 |
| Withdrew: Protocol violation | 9 | 7 |
| Withdrew: Lost to follow-up | 4 | 6 |
| Withdrew: Adverse event | 8 | 0 |
| Withdrew: Other | 0 | 3 |
| Withdrew: Physician decision | 0 | 2 |
| Withdrew: Not eligible | 1 | 1 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Randomized, but not vaccinated | 1 | 0 |
| percentage of participants | Group 1: rLP2086 + Repevax | Group 2: Saline+Repevax |
|---|---|---|
| Diphtheria | 99.4 | 99.4 |
| Tetanus | 100.0 | 100.0 |
| Pertussis toxoid | 94.7 | 96.0 |
| Pertussis filamentous hemagglutinin | 100.0 | 100.0 |
| Pertussis pertactin | 100.0 | 100.0 |
| Pertussis fimbrial agglutinogens types 2+3 | 97.6 | 98.9 |
| Poliovirus type 1 | 100.0 | 100.0 |
| Poliovirus type 2 | 100.0 | 100.0 |
| Poliovirus type 3 | 100.0 | 100.0 |
| International Units per milliliter | Group 1: rLP2086 + Repevax | Group 2: Saline+Repevax |
|---|---|---|
| Diphtheria | 1.4 (1.28 to 1.55) | 1.5 (1.34 to 1.63) |
| Tetanus | 12.3 (11.50 to 13.11) | 12.4 (11.52 to 13.25) |
Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EU/mL)
| EU/mL | Group 1: rLP2086 + Repevax | Group 2: Saline+Repevax |
|---|---|---|
| Pertussis toxoid | 27.1 (24.45 to 30.07) | 26.5 (23.95 to 29.38) |
| Pertussis filamentous hemagglutinin | 119.4 (111.15 to 128.17) | 122.9 (115.14 to 131.13) |
| Pertussis pertactin | 317.0 (285.64 to 351.80) | 336.1 (305.82 to 369.30) |
| Pertussis fimbrial agglutinogens types 2+3 | 339.1 (296.35 to 387.94) | 364.5 (320.62 to 414.42) |
| titer | Group 1: rLP2086 + Repevax | Group 2: Saline+Repevax |
|---|---|---|
| Poliovirus type 1 | 662.1 (567.36 to 772.67) | 672.6 (581.87 to 777.55) |
| Poliovirus type 2 | 840.5 (725.11 to 974.29) | 995.8 (860.54 to 1152.41) |
| Poliovirus type 3 | 2237.4 (1945.81 to 2572.65) | 2450.1 (2152.60 to 2788.70) |
| percentage of participants | Group 1: rLP2086 + Repevax | Group 2: Saline+Repevax |
|---|---|---|
| PMB80 [A22] 1:16 (N=158, 166) | 95.6 | 19.9 |
| PMB2001 [A56] 1:8 (N=148, 152) | 100.0 | 26.3 |
| PMB2948 [B24] 1:8 (N=157, 170) | 96.8 | 12.9 |
| PMB2707 [B44] 1:8 (N=146, 159) | 81.5 | 8.2 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
| percentage of participants | Group 1: rLP2086 + Repevax | Group 2: Saline+Repevax |
|---|---|---|
| Percentage of Participants With at Least One Adverse Event (AE) | 37.4 | 40.2 |
Collected over AE reported from Vaccination 1 to 1 month after last administration of investigational product (bivalent rLP2086/saline/Repevax). SAE reported from Vaccination 1 to 6 months after last of investigational product (bivalent rLP2086/saline/Repevax).. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: rLP2086 + Repevax | — | 12/374 (3.2%) | 98/374 (26.2%) |
| Group 2: Saline+Repevax | — | 9/378 (2.4%) | 118/378 (31.2%) |
| Event | Group 1: rLP2086 + Repevax | Group 2: Saline+Repevax |
|---|---|---|
| AppendicitisInfections and infestations | 1/374 | 2/378 |
| Idiopathic thrombocytopenic purpuraBlood and lymphatic system disorders | 1/374 | 0/378 |
| Vertigo positionalEar and labyrinth disorders | 1/374 | 0/378 |
| Abdominal abscessInfections and infestations | 1/374 | 0/378 |
| Appendicitis perforatedInfections and infestations | 1/374 | 0/378 |
| Arthritis infectiveInfections and infestations | 1/374 | 0/378 |
| CellulitisInfections and infestations | 1/374 | 0/378 |
| GastroenteritisInfections and infestations | 1/374 | 0/378 |
| SinusitisInfections and infestations | 1/374 | 0/378 |
| TonsillitisInfections and infestations | 1/374 | 0/378 |
| Event | Group 1: rLP2086 + Repevax | Group 2: Saline+Repevax |
|---|---|---|
| NasopharyngitisInfections and infestations | 30/374 | 31/378 |
| PharyngitisInfections and infestations | 17/374 | 19/378 |
| Upper respiratory tract infectionInfections and infestations | 16/374 | 19/378 |
| BronchitisInfections and infestations | 9/374 | 18/378 |
| GastroenteritisInfections and infestations | 8/374 | 11/378 |
| HeadacheNervous system disorders | 9/374 | 9/378 |
| SinusitisInfections and infestations | 8/374 | 6/378 |
| Otitis mediaInfections and infestations | 3/374 | 7/378 |
| Acute tonsillitisInfections and infestations | 1/374 | 7/378 |
| TonsillitisInfections and infestations | 1/374 | 7/378 |
| Age, Customized(participants) | Group 1: rLP2086 + Repevax | Group 2: Saline+Repevax | Total |
|---|---|---|---|
| Greater than or equal (>=)11-less than (<)14years | 217 | 215 | 432 |
| >=14 years-<19 years | 156 | 161 | 317 |
| Sex: Female, Male(Participants) | Group 1: rLP2086 + Repevax | Group 2: Saline+Repevax | Total |
|---|---|---|---|
| Female | 183 | 184 | 367 |
| Male | 190 | 192 | 382 |
Ran from Mar 2011 to primary completion in Oct 2012, 18 months.
Results were first posted in Nov 2014, 2 years 1 month after primary completion.
Of 13 phase 2 interventional studies under Meningitis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 18 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: MenB-FHbp vaccine · 4CMenB vaccine